Andromeda Offers $250k Salary for Robotics Controls Role

Open Roles and Responsibilities

Andromeda Surgical is mid-build on a surgical robot that tracks its position inside the body, picks where to cut, and takes commands from an iPad, and right now the company is short the engineers who can write the software that makes any of that real. Y Combinator's company page lists Andromeda as actively hiring across four engineering roles, with a 12-person team based in San Francisco and founders Nick Damiano and Kartik Tiwari billing themselves as three-time founders each, with two YC stints between them. Four openings out of twelve people means a third of headcount is on the table, and every seat is engineering.

The most fleshed-out posting is Robotics Controls Engineer, based on-site in South San Francisco, listed as entry- or mid-level with visa sponsorship. The comp band sits at $150,000 to $250,000 plus 0.80% to 1.50% equity, posted September 6, 2026. The role is open to new graduates, but the bar inside the description is anything but junior. Andromeda asks for production C++ and Python, embedded systems work, debugging across software, controls, and hardware, and "writing tests and validation as a core part of how you build, not an afterthought." On the controls side, the posting names dynamics, state estimation, feedback control, motion planning, MPC, iLQR, and optimal control, methods more common on autonomous-vehicle or aerospace job boards than in medical-device listings.

The day-to-day scope spelled out in the posting is unusually broad for a single seat. Andromeda wants this engineer to design and implement control algorithms for robotic systems, develop production software in C++ and Python, take a feature from concept through deployment, build motion-control and estimation behaviors, debug cross-domain issues, work with cross-functional teams, and participate in real-world system validation. The "nice to have" list is where the roadmap shows: experience deploying controls in robotics, autonomous systems, aerospace, or industrial automation; MPC, iLQR, or optimal control; ROS or ROS2; robotic manipulators or multi-DOF systems; embedded systems; and startup environments.

The other three openings (Senior Software Engineer, UX Designer, Lead Hardware Engineer, and Machine Learning Engineer, per the Y Combinator listing) aren't fleshed out publicly the way the controls seat is. That tracks with what the company describes as its mission — an AI-assisted surgical system whose first-generation platform pairs a robot arm that navigates target anatomy with an iPad interface for the surgeon — and with the founders' framing of the work as "building autonomy in a fraction of the time it took for Waymo." Put another way, the four open roles are the seats that turn an autonomous-driving-grade controls and perception stack into something that operates inside a human body, not on a city street.

What Gets You Past the Interview

Andromeda's filter reads less like a checklist and more like a test of operating identity. The robotics controls posting opens with a non-negotiable: "You must be able to write and ship production code in C++ on your own." The rest of the criteria orbit that core demand, and the language used to describe non-technical candidates is just as specific as the technical bar: "real, maintainable code, not just prototypes or pseudocode."

The technical floor sits on four controls pillars: dynamics, state estimation, feedback control, and motion planning. Candidates also need a track record of implementing control algorithms in physical systems, not just simulating them. The "nice to have" list (model predictive control (MPC), iterative Linear Quadratic Regulator (iLQR), Robot Operating System / ROS2, multi-degree-of-freedom manipulators, embedded systems) signals where the team is heading, and any one of those bullets moved up the resume stack. The LinkedIn hiring post repeats the same emphasis with one extra clause that matters: "Bias toward action and comfort with ambiguity."

What separates Andromeda from a typical medical-device screener is the explicit disqualification of the research-only profile. The YC listing states plainly, "This is not a research-only role. We are looking for engineers who can bridge controls theory and implementation, write production code, and take ownership of problems from concept to deployment." In practice, that means a candidate's Git history, shipped systems, and post-deployment debugging matter more than papers. The posting calls out that discipline as a core requirement and the ability to debug issues that span software, controls, and hardware in the same sitting.

On top of that technical bar, Andromeda layers a mindset filter CEO Nick Damiano has been unusually candid about. In a 2026 interview, he described the cost of a mis-hire at a 12-person startup as existential: "Hiring somebody that doesn't work out is very costly for a startup. So we want to have people we have more conviction are going to be the right mindset fit coming in." Damiano has talked about watching strong candidates from his Zenflow days fail the Andromeda screen — capable engineers, wrong shape. His reasoning is rooted in the company's autonomy-first DNA: someone who spent fifteen years in medtech solves problems differently than someone who shipped product at an autonomous-vehicle company, and Andromeda is betting its roadmap on the latter. The "3x founders from medtech and autonomous vehicles" framing in the YC listing is a deliberate signal to applicants about which pool the company is fishing in.

The interview process itself remains mostly opaque. Glassdoor shows just one anonymous review and one interview question logged as of early September 2026, a thin sample that confirms the funnel is short rather than revealing its structure. What is documented is what the company says it rewards: ownership, comfort with incomplete information, the ability to break ambiguous problems into shippable pieces, and close collaboration across software, hardware, robotics, and clinical teams.

The practical bar that emerges: production C++ on day one, controls fundamentals you can defend in a system-level tradeoff conversation, evidence you have debugged across the stack, and a mindset tuned to autonomy work rather than traditional medtech. Candidates who show all four, in that order, are the ones who clear Andromeda's filter.

Why the Hiring Surge Now

The clearest trigger is the August 3, 2026 Series A, $15 million closed by a 12-person team that did not exist three years prior. That round is not the kind of capital event that lets a company coast; it is the kind that converts a working prototype into a hiring plan. Andromeda's own materials frame the fundraising against a specific commercial target — "the fastest surgical robot to market of all time" — and a specific first application: HoLEP, a common prostate procedure performed on more than half a million patients per year in the US alone. With clinical sites in Chile, an ASTRA trial led by Prof. Peter Gilling (the surgeon who pioneered HoLEP in 1997), and two named industrial partnerships, the company has the runway and the validation to staff up rather than stay lean.

Three milestones converge on this moment. First, the world's first robotic-assisted HoLEP (branded RoLEP) was completed at Universidad Católica in Santiago, with Dr. Cristián Trucco operating through Andromeda's tablet-based interface. Second, the company announced formal collaborations with Richard Wolf (endoscopic imaging and instrumentation) and Quanta System (holmium laser technology), the two suppliers whose hardware the procedure requires. Third, the underlying robot itself was built in roughly three months by what the team describes as a "hardware-lite" architecture, where most of the value lives in software. Each milestone creates a discrete staffing requirement: a working clinical workflow needs controls engineers to harden what the prototype already does; a multi-vendor integration needs software engineers who can sit at the intersection of perception, instrument APIs, and regulatory documentation; and a "software-as-the-product" posture needs machine learning engineers who can own the autonomy roadmap end-to-end.

The Y Combinator timeline sharpens the picture. Andromeda went through YC in Summer 2023, and the job board now lists compensation from $140K to $250K in South San Francisco with equity ranging from 0.10% to 1.50%, a band that prices above early-stage seed ranges but well below late-stage medtech, consistent with a Series A that needs to attract senior individual contributors without the overhead of a public-company structure.

The roadmap behind the requisitions is the operative question. Andromeda has publicly committed to expanding from HoLEP into additional urologic procedures and then beyond urology, and to building proprietary AI models that act as a "sous surgeon" — a surgeon-in-the-loop autonomy layer trained on thousands of cases. That is a multi-year engineering surface: perception for endoscopic video, motion planning constrained by tissue geometry, real-time controls under regulatory scrutiny, and a UX that has to win over surgeons who already blame themselves for sub-optimal outcomes in roughly one in three cases. Hiring now, rather than after FDA milestones, is a bet that the software lead time is longer than the clinical lead time.

For candidates, the implication is timing. The window in which a Series A surgical robotics company is small enough to offer meaningful equity and large enough to pay competitive base salaries is narrow, and Andromeda is in it right now.

How Andromeda's Push Squeezes the Surgical Robotics Talent Market

Andromeda's four open roles arrive at a moment when the surgical robotics talent market is already stretched thin. Since 2020, Medtronic, Stryker, Intuitive Surgical, Danaher, and Becton Dickinson have together accounted for roughly half of all robotics-related new job postings in the medical device industry, according to GlobalData. A 12-person startup posting four engineering roles at once therefore punches well above its headcount in the recruiting cycle, a third of its current team, hired externally, in a market dominated by giants with decade-long brand recognition.

The supply squeeze runs deep. Autonomous vehicles, humanoid robotics, warehouse automation, and defense are all fishing from the same shallow pool of controls and perception engineers, per a 2026 robotics hiring analysis. Surgical robotics sits inside that same squeeze, which means a startup like Andromeda is bidding for talent against companies that routinely pay 40–50% premiums over baseline to solve perception and real-world deployment problems. The result is upward pressure on every surgical robotics offer, regardless of which company writes the check.

Salary bands tell the story plainly. The posted range for a Robotics Controls Engineer runs $150,000–$250,000, with the floor alone clearing the typical industry entry-level mark. National robotics compensation data shows a December 2025 median of $156,563, with the 25th-to-75th percentile spanning $101,920 to $201,400. The top of Andromeda's band pushes past the 75th percentile into territory usually reserved for software-heavy tracks. The same data flags a 53% premium for software-focused roles over hardware-focused ones and a $193,000 California median, 81% above the non-California average. South San Francisco puts Andromeda inside the highest-paying US robotics market, and its posted ceiling suggests it is paying for the upper tail of that distribution.

That price point does two things to the rest of the field. First, it resets what candidates will accept from established players. Intuitive Surgical and Medtronic do not publicly post entry-band salaries, but their offer packages are now competing against a startup willing to reach $250,000 for a controls hire. Second, it forces every other early-stage surgical robotics challenger to decide whether to match Andromeda's cash or lean harder on equity and mission — both real levers in a market where the software-vs-hardware swing can move pay by $88,000 for the same title.

The skill priorities are shifting in lockstep. AI-exposed positions are evolving 66% faster than less-exposed roles, according to PwC's 2025 Global AI Jobs Barometer, cited in a January 2026 industry analysis, and healthcare is among the sectors most actively operationalizing AI. Within robotics hiring, "specialists are more sought after than generalists" — deep perception, motion planning, or safety-critical controls expertise carries more weight than broad familiarity. Andromeda's emphasis on autonomous navigation and safety-critical controls lines up directly with that shift, and every rival hiring manager is reading the same signal: a resume that demonstrates shipped autonomy work will get past filters faster than one that lists generic robotics experience.

The competitor response is already visible in the broader robotics ecosystem. AI specialist hiring is expanding from experimentation into operational scale, and embodied AI investment is creating roles around AI engineering, automation, and AI product development. Surgical robotics recruiters, watching startups like Andromeda compete for the same narrow candidate pool, are adjusting their shortlists in real time, screening for regulatory-aware software, FDA-adjacent process discipline, and perception systems that have run in the real world rather than only in simulation. Candidates who can credibly speak to all three are now the ones moving through pipelines at every surgical robotics company, not just the one that posted the job.

Aligning Your Background With Andromeda's Hiring Bar

Andromeda is not hiring a generalist robotics engineer and hoping they pick it up on the job. Every open role points to a single profile the company is screening for: someone who can write safety-critical controls code, ship AI perception pipelines, and defend both in front of regulators. The good news for candidates is that the prerequisites are now legible from the published research, the prototype milestones, and the failures of competing platforms. The bad news is that "legible" and "easy" are not the same thing.

Start with what the research actually shows about the engineering problems Andromeda is racing to solve. UC San Diego's July 8, 2026 Nature paper demonstrated the first teleoperated humanoid laparoscopic surgeries using a system nicknamed Surgie, and the same paper makes the technical debt painfully visible: latency sat in the hundreds of milliseconds while the surgical literature targets under 150 ms, and the Unitree G1 platform's 450 mm arm span forced "frequent repositioning and recalibration, adding more than three minutes each time." Cooling breaks after overheating were required during live porcine procedures. Every one of those pain points is a job description line in disguise. A candidate who can show prior work reducing teleoperation latency, shrinking pose-estimation or instrument-tracking error under compute constraints, or hardening a thermal envelope for a continuous-duty robotic arm is already talking Andromeda's language before they say a word about themselves.

The next move is to audit your resume against what the Surgie paper, the Ars Technica coverage, and Singularity Hub's reporting explicitly flagged as unsolved. Read those sources once, then build a one-page matrix: every cited limitation on the left, your closest project or paper on the right. Latency under load, recalibration overhead, range-of-motion constraints on compact arms, sterilization protocols for non-medical-grade hardware, camera-handoff coordination between two robot operators, and surgeon-cognitive-load reduction are all named, documented gaps. A candidate who maps even two of those gaps to shipped or published work will outrank a candidate who lists "ROS, C++, Python, PyTorch" and hopes for the best.

For interview preparation specifically, treat the regulatory framing as a first-class skill, not an afterthought. The Intuitive da Vinci platform still dominates because it is FDA-cleared and trial-validated; the humanoid approach is "still very much in the experimental phase," according to Ars Technica. Andromeda has to close that gap to ship, so interviewers will probe whether a candidate understands what an FDA submission actually demands: traceability of requirements, formal hazard analysis, software-of-unknown-provenance discipline, and IEC 62304-style lifecycle thinking. You do not need to be a regulatory affairs hire. You do need to be able to discuss, in concrete terms, how you would design a controls loop so that every state is logged, every fault is bounded, and every behavior under degraded sensing is specifiable in advance.

Finally, frame your portfolio around the team story the research tells, not the solo-hero story. The UC San Diego work explicitly demonstrated three configurations: a human surgeon leading a humanoid assistant, two humanoids working side by side with a human assistant stepping aside for camera duty, and the long-term autonomous-assistant vision articulated for the field. Candidates who have shipped multi-agent coordination, leader-follower handover, or shared-autonomy arbitration will read as native to that roadmap. Candidates who only have single-robot, single-operator demos will read as solving yesterday's problem.

One tension worth flagging: Andromeda's hiring surge implies a confident product roadmap, but the underlying humanoid-surgery research is preclinical, with multiple unresolved safety and latency issues publicly documented. Candidates betting their next two years on this stack should ask, in the interview, exactly which of those named gaps the role owns, and whether the answer matches the job posting.

Working in frontier tech? Zero G Talent tracks the openings: see every open ASML role, browse frontier tech jobs, openings at Stripe, and the people building the field.